PI3K inhibitors in haematological malignancies.

Brown, Jennifer R; Danilov, Alexey V; LaCasce, Ann S; Davids, Matthew S

Brown, Jennifer R; Danilov, Alexey V; LaCasce, Ann S; Davids, Matthew S.

Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: jennifer_brown@dfci.harvard.edu.
Danilov AV; Department of Haematology, City of Hope National Medical Center, Duarte, CA, USA.
LaCasce AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Lancet Oncol ; 23(8): e364, 2022 08.

Article in English | MEDLINE | ID: covidwho-2253100

Subject(s)

Hematologic Neoplasms; Phosphatidylinositol 3-Kinases; Hematologic Neoplasms/drug therapy; Humans; Phosphoinositide-3 Kinase Inhibitors/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / Phosphatidylinositol 3-Kinases Limits: Humans Language: English Journal: Lancet Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google